Latest Market Expansion News

BluGlass Limited has secured over A$4 million in new contracts and filed three US patents for high-power tunable GaN lasers, reinforcing its leadership in visible laser technology and expanding its footprint in strategic photonics markets.

1414 Degrees Ltd reports strong progress in its hydrogen and thermal energy storage projects, securing full funding for commercialisation and advancing key customer agreements. The company is poised to scale its innovative technologies amid ongoing operational enhancements.

archTIS Limited reported a 12% increase in annual recurring revenue to $4 million and achieved net positive cash flow from operations, while signing a binding term sheet to acquire Direktiv’s assets, signaling strategic growth in data-centric security.

Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.

Control Bionics has delivered its strongest US sales quarter in years, nearing US$1 million in revenue, while broadening its market footprint with new commercial agreements and cost optimizations.

Live Verdure Ltd has secured a controlling stake in AI innovator Decidr.ai and reported robust e-commerce growth for its Edible Beauty brand, underscoring its strategic pivot towards AI-driven expansion.

Little Green Pharma reports a robust 75% revenue increase to $9.5 million for December quarter, driven by strong European market growth and strategic product launches.

BirdDog Technology reports a strategic pivot with four next-generation product launches, a 20% price increase, and a robust cash position, despite a 13% revenue decline in H1 FY25.

Volt Group Limited reported a robust 20% increase in FY24 revenue receipts, driven by strong EcoQuip growth and strategic contract wins, while advancing its zero-emission ATEN technology with promising trials underway.

First Graphene Limited reports a robust December quarter with new patents, expanded distribution networks, and advancing commercial trials, positioning the company on a path to cash breakeven.

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.

Terragen Holdings reports robust quarterly progress, highlighted by successful beef feedlot trials and a $4.76 million equity raise, setting the stage for its new probiotic product launch in March 2025.